Evaluation of lymphocytes inactivation by extracorporeal photopheresis using tetrazolium salt based-assay. Issue 2 (October 2015)

• Record Type: Journal Article
• Authors: Chieregato, Katia; Alghisi, Alberta; Borghero, Carlo; Elice, Francesca; Raimondi, Roberto; Zanetti, Ermella; Rodeghiero, Francesco; Astori, Giuseppe
• Is Part Of: Transfusion and apheresis science. Volume 53:Issue 2(2015)
• Page Start: 242
• Page End: 245
• Publication Date: 2015-10
• Subjects: Extracorporeal photopheresis -- ECP -- Flow cytometry -- Tetrazolium salt -- CFSE; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2015.05.004
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Extracorporeal photopheresis (ECP) is accepted as a second-line therapy for the treatment of acute and chronic steroid-refractory graft versus host disease (GvHD), cutaneous T-cell lymphoma and solid organ transplantation. ECP should be validated: we compared in parallel apoptosis and proliferation analysis of patient lymphocytes treated with 8-MOP ECP using respectively Annexin V/7-aminoactinomycin D (7-AAD) and CFSE with a tetrazolium salt (WST-1) method. Using WST-1 assay we found a significant decrement (p < 0.01) of metabolic activity at 4 days between ECP-treated and untreated cells. This finding was confirmed by the significant decrease of cell proliferation and increase of cell death observed by CFSE and 7AAD-Annexin V, respectively. Accordingly, once validated against a reference method, WST-1 could represent a rapid and easy assay for routinely quality control of ECP.